(Q30243961)

12 June 2017

1 reference

title

Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project (English)

1 reference

12 June 2017

1 reference

3

Anke Huckriede

1 reference

12 June 2017

7

Guus Rimmelzwaan

1 reference

12 June 2017

Heng Liu

1

1 reference

12 June 2017

Henderik W Frijlink

2

1 reference

12 June 2017

Eva van Doorn

4

1 reference

12 June 2017

Ed Schmidt

5

1 reference

12 June 2017

Odile Leroy

6

1 reference

12 June 2017

Keneth McCullough

8

1 reference

12 June 2017

Mike Whelan

9

1 reference

12 June 2017

Eelko Hak

10

1 reference

12 June 2017

language of work or name

English

0 references

publication date

25 October 2016

1 reference

12 June 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

12 June 2017

volume

34

1 reference

12 June 2017

issue

48

1 reference

12 June 2017

page(s)

5845-5854

1 reference

After flu vaccine mismatch, calls for delayed selection intensify.

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Therapeutic and prophylactic applications of alphavirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Self-replicating Replicon-RNA Delivery to Dendritic Cells by Chitosan-nanoparticles for Translation In Vitro and In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A review of the changes to the licensing of influenza vaccines in Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

The challenge of developing universal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Adjuvants for human vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Influenza Immunization: Field Trial on a University Campus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Devices and formulations for pulmonary vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Needle-free influenza vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Advances in the development of influenza virus vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

Influenza-Specific Antibody-Dependent Phagocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.040

10.1016/J.VACCINE.2016.10.040

7 January 2021

Identifiers

DOI

1 reference

12 June 2017

1 reference